1. Volume 12, Issue 8, Pages 743-752 (August 2011)
Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial 
Prof Gareth J Morgan, MD, Prof J Anthony Child, MD, Prof Walter M Gregory, PhD, Alex J Szubert, MSc, Kim Cocks, MSc, Sue E Bell, DPhil, Nuria Navarro-Coy, MPhil, Mark T Drayson, MD, Roger G Owen, MD, Sylvia Feyler, MD, A John Ashcroft, MD, Fiona M Ross, DPhil, Jennifer Byrne, MD, Huw Roddie, MD, Claudius Rudin, MD, Gordon Cook, MD, Prof Graham H Jackson, MD, Ping Wu, MSc, Faith E Davies, MD 
The Lancet Oncology 
Volume 12, Issue 8, Pages (August 2011)
DOI: /S (11)
Copyright © 2011 Elsevier Ltd Terms and Conditions

2. Figure 1
Trial profile
The complete trial protocol is provided in Morgan and colleagues.12 CVAD=cyclophosphamide, vincristine, doxorubicin, and dexamethasone. CTD=cyclophosphamide, thalidomide, and dexamethasone. MP=melphalan and prednisolone. CTDa=attenuated CTD.
The Lancet Oncology  , DOI: ( /S (11) )
Copyright © 2011 Elsevier Ltd Terms and Conditions

3. Figure 2
Time to first skeletal-related event overall (A), in patients with bone lesions at baseline (B), and in patients without bone lesions at baseline (C)
HR=hazard ratio. *Cox p value.
The Lancet Oncology  , DOI: ( /S (11) )
Copyright © 2011 Elsevier Ltd Terms and Conditions

4. Figure 3
Proportion of patients with an on-study skeletal-related event overall (A), with bone lesions at baseline (B), and without bone lesions at baseline (C)
The Lancet Oncology  , DOI: ( /S (11) )
Copyright © 2011 Elsevier Ltd Terms and Conditions